Wells Fargo & Company Satsuma Pharmaceuticals, Inc. Transaction History

Wells Fargo & Company

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$0.7 - $1.07 $2 - $3	3 Added 1.65%	185 $0
Q4 2022 Feb 13, 2023	BUY	$0.61 - $5.06 $29 - $242	48 Added 35.82%	182 $0
Q3 2022 Nov 14, 2022	BUY	$4.19 - $7.95 $67 - $127	16 Added 13.56%	134 $1,000
Q2 2022 Aug 12, 2022	BUY	$2.59 - $4.3 $23 - $38	9 Added 8.26%	118 $0
Q1 2022 May 16, 2022	BUY	$3.78 - $5.32 $3 - $5	1 Added 0.93%	109 $0
Q3 2021 Nov 15, 2021	BUY	$4.54 - $7.17 $258 - $408	57 Added 111.76%	108 $1,000
Q2 2021 Aug 16, 2021	SELL	$4.8 - $7.25 $15,523 - $23,446	-3,234 Reduced 98.45%	51 $0
Q1 2021 May 13, 2021	SELL	$4.57 - $7.18 $20,025 - $31,462	-4,382 Reduced 57.15%	3,285 $19,000
Q4 2020 Feb 09, 2021	BUY	$3.56 - $5.09 $8,109 - $11,595	2,278 Added 42.27%	7,667 $35,000
Q3 2020 Nov 05, 2020	SELL	$3.85 - $28.47 $9,309 - $68,840	-2,418 Reduced 30.97%	5,389 $21,000
Q2 2020 Aug 13, 2020	BUY	$16.01 - $34.69 $73,133 - $158,463	4,568 Added 141.03%	7,807 $225,000
Q1 2020 May 14, 2020	BUY	$14.53 - $30.69 $47,062 - $99,404	3,239 New	3,239 $70,000

Ticker STSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,587,500
Description
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can ...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.